Clinical Trials Directory

Trials / Completed

CompletedNCT03996720

Early Identification and Effective Management of Pediatric Sepsis

Integration of Metabolic and Inflammatory Mediator Profiles as a Potential Diagnostic Approach for Severe Sepsis in PICU

Status
Completed
Phase
Study type
Observational
Enrollment
175 (actual)
Sponsor
Children's Hospital of Fudan University · Academic / Other
Sex
All
Age
29 Days – 18 Years
Healthy volunteers

Summary

In patients diagnosed as sepsis on PICU admission, early and accurate identification of patients who will develop organ dysfunction (severe sepsis) is critical for effective management and positive outcome. A multiple marker approach would improve clinical utility compared with use of a single marker. The primary goal of this part of study is to define a combination of multiple markers, derived from novel biomarkers (nCD-64, IL-27, sTREM, HLA-DR, IL-10), metabolomics and routine clinical parameters, which could predict severe sepsis and determine the severity of disease.

Detailed description

We intend to enroll pediatric sepsis patients at four PICUs and divide them into two groups based on clinical outcomes: severe sepsis group (patients who progress into severe sepsis), sepsis group (patients who do not progress in to severe sepsis). We intend to perform predictive modeling using multivariable analyses of the novel biomarkers and derive a biomarker panel and algorithm for early diagnosis of severe sepsis. The predictive value of the biomarker panel for early identification of severe sepsis will be compared with established indices, such as PRISM III and pSOFA score.

Conditions

Timeline

Start date
2018-10-01
Primary completion
2021-06-30
Completion
2021-09-30
First posted
2019-06-25
Last updated
2021-10-12

Locations

4 sites across 1 country: China

Source: ClinicalTrials.gov record NCT03996720. Inclusion in this directory is not an endorsement.